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The elderly population is one of the most vulnerable groups to influenza infection and influenza-related 
complications. Unfortunately, vaccination exhibits reduced efficacy in this population. Immunization and 
treatment with passive antibody transfer could therefore be a valuable alternative. 
 
In this project, we have generated antibodies against a constant region of hemagglutinin (HA), the main protein 
found at the surface of the virus. In vitro, two lead candidates (mAb 10A9 and mAb 11H12) were able to detect 
strains belonging to 13 subtypes of Influenza A as well as B strains (1). In order to facilitate large scale 
production, stable CHO pools were generated for pan-HA antibody production. Biophysical characteristics of 
antibodies produced in CHO cells were similar to the ones of antibodies generated using mouse hybridomas. 
The antibodies were further tested in a mouse model of influenza to evaluate their protective potential.   
 
The antibodies offered protection against influenza regardless of their production platform (Figure 1). The CHO-
produced antibody was tested in prophylactic mode (first injection 24hrs before the challenge) and as a 
therapeutic (first treatment 4hrs after viral infection). In both cases, all mice survived. Other viral strains and 
treatment regimens have to be tested but these preliminary results are encouraging. 
 
Finally, multiple repeated administrations of the mAb in at-risk population would be impractical and too 
expensive. Therefore, recombinant Adeno-Associated-Virus (rAAV) is being considered as a delivery system. 
Using rAAV would allow delivering the genes encoding for the mAb and ensuring their long-term expression. 
The heavy chain and light chain of the pan-HA antibodies are expressed on the same cassette and transfected 
into suspension HEK293SF cells, along with two other plasmids to form the AAV particles. After purification, the 
AAV will be injected in mice for long term production of the antibodies (experiments ongoing). This would 
represent a cost effective delivery route in immunocompromised or elderly individuals.  
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Figure 1 – Protective effect of 15 µg/g body weight of mAb 10A9 (produced from mouse hybridoma or CHO 
cells) against H3N2 A/Hong Kong/8/68 in BALB/c mice (n= 5 per group).Mice were infected with 104PFU virus 
by intranasal challenge. The different injection times relative to infection are shown in the legend in brackets. 
